UsAgainstAlzheimer’s Congratulates Dr. Robert Califf on Confirmation as New FDA Commissioner by U.S. Senate

Washington, DC (February 15, 2022) – Today, the United States Senate confirmed Dr. Robert Califf as the new commissioner of the Food and Drug Administration (FDA). Dr. Califf’s demonstrated professionalism and strategic vision for the future of the agency earned him bipartisan support from a range of senators. The confirmation is a victory for Americans who are looking to the FDA for thorough and expeditious consideration of potential treatments for conditions like Alzheimer’s disease.  

“Patients and their families can rest easier knowing we have an ally in Dr. Califf leading the FDA,” said George Vradenburg, chair and co-founder of UsAgainstAlzheimer’s. “He expertly balances the agency’s vital authority to approve needed treatments while considering the broader impact these drugs will have in the lives of everyday Americans. This is most evident in his support for the principled use of the Accelerated Approval Program, which has already been used with more than 250 drugs.”

As an organization that is committed to innovation and scientific-driven solutions, UsAgainstAlzheimer’s commended President Joe Biden on his choice to nominate Dr. Califf and the U.S. Senate in their decision to confirm him.  

“Dr. Califf will be a critical part of the Biden Administration’s work to apply the lessons of the COVID-19 pandemic to other public health crises in America,” said Vradenburg. “Whether it’s the fight against Alzheimer’s, cancer, or other serious illnesses, Dr. Califf has the experience and patient-centered approach that is necessary to succeed in this role again.”

For more information on UsAgainstAlzeimer’s and our work to ensure FDA-approved treatments are available to all Americans, read more here.



About UsAgainstAlzheimer’s
UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. We take on the toughest problems; bring all of “Us” together to break down barriers; advocate for research that will speed treatments to market; and drive changes that matter most to people living with the disease. We will not rest until brain-span equals lifespan - for everyone.